Navigation Links
Halozyme To Present New Data On PEGPH20 In Pancreatic Cancer At American Society of Clinical Oncology Annual Meeting
Date:5/15/2013

SAN DIEGO, May 15, 2013 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that clinical data from a Phase 1b trial of PEGPH20 (PEGylated Recombinant Human Hyaluronidase), an investigational new biologic, in combination with gemcitabine for treatment of patients with stage IV metastatic pancreatic cancer will be presented at the 2013 American Society of Clinical Oncology (ASCO) Annual Meeting.

(Logo: http://photos.prnewswire.com/prnh/20100302/LA63139LOGO)

In this Phase 1b study, 28 stage IV pancreatic ductal adenocarcinoma patients were treated with PEGPH20 in combination with gemcitabine. The overall response rate (CR+PR) was 42 percent* (n=24) as assessed by independent review at therapeutic dose levels of PEGPH20 (1.6 and 3.0 µg/kg). Treatment was generally well tolerated and the adverse event profile was consistent with those seen in previous studies of PEGPH20 as a single agent and as previously reported for gemcitabine alone. There was no evidence of new observed toxicity. Detailed clinical data, including CA 19-9 and pharmacodynamic results will be presented at the meeting.

Emerging data show that most pancreatic cancers surround themselves with a protective hyaluronan-rich matrix, which makes the disease difficult to treat and is itself an indicator of poor prognosis. PEGPH20 depletes this matrix component from the tumor and rapidly changes the tumor microenvironment and metabolism, which may render it more vulnerable to therapy as well as inhibit tumor growth.

"Data from this single arm Phase 1b study clearly reinforce the hypothesis of treating pancreatic cancer with PEGPH20 in conjunction with chemotherapeutic agents," said Joy Zhu , M.D., Ph.D., Vice President, Oncology Clinical Development,
'/>"/>

SOURCE Halozyme Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Halozyme Therapeutics to Present at the 30th Annual J.P. Morgan Healthcare Conference
2. Halozyme to Host Fourth Quarter and 2011 Year-End Financial Results Conference Call
3. Halozyme Therapeutics to Present at Two Upcoming Investor Conferences in March
4. Halozyme to Host Second Quarter Financial Results Conference Call
5. Halozyme to Host Fourth Quarter and 2012 Year-End Financial Results Conference Call
6. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
7. ChemoCentryx Presents Positive Results for Novel CCR2 Inhibitor in Preclinical Models of Diabetic Nephropathy at the 44th Annual Meeting of the American Society of Nephrology
8. Organovo to Present at Lazard Capital Markets 8th Annual Healthcare Conference
9. Chimerix Announces Late-Breaking Poster Presentation at Kidney Week 2011 Annual Meeting
10. Pharmasset to Present at the Lazard Capital Markets Healthcare Conference
11. Masimo to Present at 23rd Annual Piper Jaffray Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... France and Dallas, TX, USA (PRWEB) , ... ... ... of innovative nano and microsystems, has appointed Francois Vieillard as Sales & Marketing ... Marketing at executive positions, Francois Vieillard will be responsible for reinforcing Tronics’ business ...
(Date:7/30/2015)... , July 30, 2015 ... by Product (Software, Molecular Modeling, PB/PK, PKPD, Trial Design, ... & Development, Preclinical, Clinical Trial), by End Users - ... Market is expected to reach USD 2,107.99 million by ... CAGR of 15.29%. Browse more than ...
(Date:7/30/2015)... 30, 2015   Aratana Therapeutics, Inc . ... focused on the licensing, development and commercialization of ... that its strategic partner VetStem Biopharma, Inc. has ... of AT-016, an adipose-derived allogeneic stem cell product ... osteoarthritis pain in dogs. The double-blinded, ...
(Date:7/30/2015)... the globe, ISN improves the efficiency and effectiveness of contractor management systems. ISN,s online ... contractors in over 80 countries. ... ... Over 60,000 Worldwide Customers In More Than 80 Countries ... in Dallas, TX , ISN has additional offices in Calgary ...
Breaking Biology Technology:Tronics appoints Francois Vieillard as Sales and Marketing Director 2Biosimulation Market Worth 2,107.99 Million USD by 2020 2Biosimulation Market Worth 2,107.99 Million USD by 2020 3Biosimulation Market Worth 2,107.99 Million USD by 2020 4Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 2Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 3Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 4Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 5ISN Reaches Over 60,000 Worldwide Customers 2ISN Reaches Over 60,000 Worldwide Customers 3
... 27, 2010 , , , ... - New Trial Results on ExoSeal(TM) Vascular Closure Device Support its,Clinical Safety* and Efficacy ... Cordis Corporation, a worldwide ... Vascular Closure Device. ExoSeal(TM) incorporates a number of new,advances in technology and simplicity of ...
... ,,, ... 26, 2010, QIAGEN N.V. (NASDAQ: ... Prime Standard: QIA [, http://www.boerse-frankfurt.de/DE/index.aspx?pageID=35&ISIN=NL0000240000 ... an agreement with Roche Molecular Systems,Inc., ...
... increase crop yields and productivity, create sustainable forests and new medicines, and ... in the world,s poorest countries, will be among the recurring themes of ... Congress, June 6-11, 2010 , at the America,s Center ... , , ...
Cached Biology Technology:CORDIS Launches ExoSeal(TM) Vascular Closure Device 2CORDIS Launches ExoSeal(TM) Vascular Closure Device 3CORDIS Launches ExoSeal(TM) Vascular Closure Device 4QIAGEN and Roche Settle Dispute Over Distribution Agreement for TheraScreen Companion Diagnostics 2QIAGEN and Roche Settle Dispute Over Distribution Agreement for TheraScreen Companion Diagnostics 3QIAGEN and Roche Settle Dispute Over Distribution Agreement for TheraScreen Companion Diagnostics 4QIAGEN and Roche Settle Dispute Over Distribution Agreement for TheraScreen Companion Diagnostics 5QIAGEN and Roche Settle Dispute Over Distribution Agreement for TheraScreen Companion Diagnostics 6Plant BioTech World Congress to Highlight Scientific Discoveries and Technologies Bringing New Hope to Feeding the World and Improving Lives 2Plant BioTech World Congress to Highlight Scientific Discoveries and Technologies Bringing New Hope to Feeding the World and Improving Lives 3
(Date:7/9/2015)... -- Research and Markets( http://www.researchandmarkets.com/research/98rrmr/biometrics_for ... "Biometrics for Banking; Market & Technology Analysis, Adoption ... offering. The adoption for banking purposes ... the forecast is that by 2020 it will ... in delivering biometric systems to the banking industry. ...
(Date:7/8/2015)... DIEGO , July 8, 2015  Trovagene, ... cell-free molecular diagnostics, today announced the launch of ... the Company,s Precision Cancer Monitoring℠ (PCM) technology for ... receiving one or a combination of the novel ... Opdivo® (nivolumab), a PD-1 inhibitor. The 50-patient study ...
(Date:7/2/2015)... June 25, 2015 ... addition of the "Natural Language Processing Market ... IVR, OCR, Pattern & Image Recognition) - Worldwide ... The key vendors occupying the market ... Corporation, Microsoft Corporation, NetBase Solutions, SAS Institute Inc., ...
Breaking Biology News(10 mins):Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 2Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4Natural Language Processing Market by Type (Rule-Based, Statistical, and Hybrid), Technologies (Recognition, IVR, OCR, Pattern & Image Recognition) - Worldwide Forecast to 2020 2
... uncovered an important step in how herpes simplex virus, ... to gain entry into healthy cells and infect them. ... the effectiveness of monitoring these protein interactions using biomolecular ... the National Academy of Sciences, provide a better understanding ...
... Access publisher for Physics, Mathematics and Computer Science, ... DESY high-energy physics laboratories. Under these agreements ... all research published by their investigators in the ... PMC Physics A is edited by professor Ken ...
... connect silicon circuits with brains are under intensive ... commercial application in many areas, according to a ... Berger of the University of Southern California chaired ... of Research and Development in Brain-Computer Interfaces," published ...
Cached Biology News:Penn researchers shine the light of venus to learn how the herpes virus invades cells 2Top physics laboratories sign up to open access with PhysMath Central 2Brain-computer link systems on the brink of breakthrough, study finds 2
Complete cell culture media with cytokines...
8 different frozen tissues are mounted on positively charged glass slides...
Donor feline serum and plasma...
... vacuum cups provide flexible sealing lips ... irregular surfaces. ,PFG: Flat cup ,PBG: ... ,PCG: Multiple Bellows cup , ... to 200 mm , Multiple suction ...
Biology Products: